Kaiser Permanente Gives Green Signal for the Commercial Use of Cxbladder

  • Jun 17, 2020 NZST
  • Team Kalkine
Kaiser Permanente Gives Green Signal for the Commercial Use of Cxbladder

Pacific Edge Limited (NZX:PEB) and Kaiser Permanente, a US healthcare provider, have agreed for the commercial use of the PEB’s Cxbladder tests. Kaiser Permanente has allowed the commercial use of Cxbladder by their urologists for patients being assessed for bladder cancer.

  • Kaiser Permanente is one of the biggest non-profit healthcare providers in the US and has more than 12 million members;
  • It operates 39 hospitals and employs approximately 23,000 physicians.

The stock of PEB is up by 75.57% to $0.230 as at 1:41 pm.

 


Disclaimer
The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. Kalkine does not in any way endorse or recommend individuals, products or services that may be discussed on this site.

 

   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK